Results 261 to 270 of about 72,644 (316)

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [PDF]

, 2017
Felip, E., Lievens, Y., Stahel, R. A., Weder, W.   +3 more
core  

Transfer learning approach in pre-treatment CT images to predict therapeutic response in advanced malignant pleural mesothelioma. [PDF]

Front Oncol
Fanizzi A, Catino A, Bove S, Comes MC, Montrone M, Sicolo A, Signorile R, Perrotti P, Pizzutilo P, Galetta D, Massafra R.   +10 more
europepmc   +1 more source

YAP/TAZ-TEAD signalling axis: A new therapeutic target in malignant pleural mesothelioma. [PDF]

J Cell Mol Med
Papavassiliou KA, Sofianidi AA, Papavassiliou AG.   +2 more
europepmc   +1 more source

Characterizing soluble immune checkpoint molecules and TGF-β_1,2,3 in pleural effusion of malignant pleural mesothelioma. [PDF]

Sci Rep
Okita R, Senoo T, Mimura-Kimura Y, Mimura Y, Murakami T, Ikeda E, Okada M, Inokawa H, Aoe K.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Malignant pleural mesothelioma

BMJ Case Reports
Malignant pleural mesothelioma is a rare and aggressive tumour of the pleura, commonly linked to asbestos exposure. However, its diagnosis is challenging, especially without known exposure.
Pragati Rao D, Sruthy Vijayan, Shashidhar S Vananjakar, Prasanna Kumar T   +3 more
semanticscholar   +3 more sources

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Journal of Clinical Oncology, 2003
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy.
N. Vogelzang, J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffié, U. Gatzemeier, M. Boyer, S. Emri, C. Manegold, C. Niyikiza, P. Paoletti   +11 more
semanticscholar   +1 more source

Malignant Pleural Mesothelioma

Current Oncology Reports, 2011
Malignant pleural mesothelioma (MPM) is a relatively rare thoracic malignancy accounting for about 2000-3000 new cases per year. This cancer has been increasing in incidence and is strongly associated with asbestos exposure. Also, it is characterized by insidious growth and clinical presentation at an advanced stage of disease.
Siva Raja, Sudish C. Murthy, David P. Mason   +2 more
openaire   +5 more sources

Abemaciclib for malignant pleural mesothelioma

The Lancet Oncology, 2022
No abstract ...
Nardone, Valerio, Porta, Camillo, Giannicola, Rocco, Correale, Pierpaolo, Mutti, Luciano   +4 more
openaire   +3 more sources

Abstract LB-331: Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations

, 2016
Malignant pleural mesothelioma (MPM) is an aggressive cancer arising from the mesothelial cells of the pleura. About 80% of mesothelioma cases are linked to asbestos exposure, while the remainder may be related to prior chest radiation, genetic ...
S. Seshagiri, E. Stawiski, L. Goldstein, S. Durinck, Z. Modrusan, Florian Gnad, Thong T. Nguyen, B. Jaiswal, A. Rienzo, W. Richards, R. Bueno   +10 more
semanticscholar   +1 more source